LMU Munich at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
LMU Munich brings 5 presentations to ESGCT 2026 in Hamburg. Its work covers AAV vector biology in the retina and peptide-based lipid nanoparticles for mRNA delivery. Other strands cover a dual AAV therapy for Stargardt disease moving towards the clinic and how tumours escape CAR T cells by losing the target antigen.
| Organization | ESGCT 2026 Attendance |
|---|---|
LMU Munich Munich, Germany | |
Public research university in Munich, with research on AAV vectors and nucleic acid delivery. | Talk Tue Oct 27 6:30pm–7:30pm Affinity proteomics-based receptor screening reveals capsid-dependent host interactions of AAV vectors in the retina Vectors and delivery (AAV, lentiviral, LNP) Talk Wed Oct 28 9:45am–10:30am Hydrophobic Tuning and Surface Modification of Lipo-Xenopeptide mRNA Polyplexes in Different Cell Models In Vitro and In Vivo Vectors and delivery (AAV, lentiviral, LNP)RNA and oligonucleotide therapies Talk Wed Oct 28 12:00pm–12:30pm Clinical translation of a dual AAV gene therapy for ABCA4-associated Stargardt disease Vectors and delivery (AAV, lentiviral, LNP)Rare and inherited disease Poster Thu Oct 29 2:00pm–4:00pm Enhanced intramuscular mRNA activity of peptide lipid nanoparticles with hydrophobized head groups Poster Thu Oct 29 2:00pm–4:00pm Investigating Antigen Escape-Mediated Resistance to CAR-T Cell therapy in B-ALL and Multiple Myeloma through Base-Editing Tiling Screens and Functional Validation |
Instantly find 20 buyers from LMU Munich
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction